OptimizeRx(OPRX) - 2024 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For fiscal year 2024, the company reported revenue of $92.1 million and adjusted EBITDA of $11.7 million, exceeding guidance and street expectations [7] - Fourth quarter revenue was $32.3 million, a 14% increase from $28.4 million in the same period of 2023, driven by increased DAAP-related revenue streams [19] - Gross margin improved from 62.9% in Q4 2023 to 68.2% in Q4 2024, attributed to a favorable solution and channel partner mix [19] - Net loss for Q4 2024 was $0.1 million, significantly improved from a net loss of $4.1 million in Q4 2023 [21] - Non-GAAP net income for Q4 2024 was $5.5 million, or $0.30 per diluted share, compared to $4.6 million, or $0.26 per diluted share in the prior year [21] - Adjusted EBITDA for Q4 2024 was $8.8 million, up from $5.8 million in Q4 2023 [21] Business Line Data and Key Metrics Changes - The average revenue for the top 20 pharmaceutical manufacturers was $2.9 million, a 22% increase year-over-year [23] - The top five customers averaged over $9 million in revenue in 2024, with plans to elevate at least one more customer to this level in 2025 [12] Market Data and Key Metrics Changes - The net revenue retention rate improved to 121%, up from 105% in the previous year [23] - Revenue per FTE increased to $701,000, compared to $586,000 in the prior year [23] Company Strategy and Development Direction - The company aims to focus on operational excellence and customer centricity while transitioning to a subscription-based revenue model [5][6] - Plans to become a "Rule of 40" company over the next several years, emphasizing substantial operating leverage and predictable revenue streams [15][16] - The company is positioned in a $10 billion total addressable market with significant growth opportunities driven by increased pharma advertising spend on digital channels [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory and the strong demand for audience creation and dynamic audiences [48] - The company is committed to under-promising and over-delivering, maintaining a conservative approach while being encouraged by current visibility in the business [71] - The management highlighted the importance of monitoring FDA approvals and their impact on the pharmaceutical market [78] Other Important Information - The company completed the Medicx Health acquisition in Q4 2023, which is expected to enhance its service offerings and operational efficiency [20] - The transition from managed services to self-service for Medicx is largely complete, with growth in audience components being a key focus [100] Q&A Session Summary Question: Focus on customer centricity and strategy changes - Management emphasized increasing customer centricity and making it easier for clients to renew and expand their footprint [30] Question: Impact of subscription-based revenue model - The transition to a subscription model is expected to create more predictable and stickier revenue, particularly from the data component of DAAP deals [36] Question: Gross margin expansion drivers - Gross margin expansion was driven by product mix, particularly from DAAP, and while current margins are high, they may not be sustainable at that level [45][46] Question: Visibility into new DAAP deals and backlog - The company is seeing strong demand for DAAP solutions, with visibility into 2025 being significantly stronger than the previous year [52] Question: Timeframe for becoming a Rule of 40 company - Management indicated that achieving the Rule of 40 is a multi-year journey, likely taking 3 to 5 years [58] Question: Baseline growth expectations for next year - Management is optimistic about growth but will maintain a conservative approach in forecasting [70] Question: Customer acquisition costs for data vs transactional components - There is no material difference in customer acquisition costs between data and transactional components [90] Question: Transition of Medicx business from managed to self-service - The transition is largely complete, with growth in high-margin audience components being a focus [99]